Uni Qure N.V. QURE
We take great care to ensure that the data presented and summarized in this overview for uniQure N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding QURE
View all-
Vestal Point Capital, LP New York, NY4.75MShares$35.4 Million1.78% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.78MShares$20.7 Million0.81% of portfolio
-
Boxer Capital, LLC San Diego, CA2.23MShares$16.6 Million0.58% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.19MShares$16.3 Million0.01% of portfolio
-
Abrdn PLC1.93MShares$14.4 Million0.02% of portfolio
-
Black Rock Inc. New York, NY1.93MShares$14.3 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY1.85MShares$13.8 Million0.83% of portfolio
-
Franklin Resources Inc San Mateo, CA1.49MShares$11.1 Million0.0% of portfolio
-
Schroder Investment Management Group London, X01.47MShares$10.9 Million0.01% of portfolio
-
International Biotechnology Trust PLC London, X01.24MShares$9.25 Million2.83% of portfolio
Latest Institutional Activity in QURE
Top Purchases
Top Sells
About QURE
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Transactions at QURE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2024
|
Matthew C Kapusta CEO, Managing Director |
SELL
Open market or private sale
|
Direct |
100,000
-14.33%
|
$1,500,000
$15.03 P/Share
|
|
Dec 10
2024
|
Matthew C Kapusta CEO, Managing Director |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+12.53%
|
$1,400,000
$14.71 P/Share
|
|
Dec 09
2024
|
Matthew C Kapusta CEO, Managing Director |
SELL
Open market or private sale
|
Direct |
3,418
-0.57%
|
$23,926
$7.63 P/Share
|
|
Dec 09
2024
|
Christian Klemt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,796
-1.07%
|
$12,572
$7.55 P/Share
|
|
Dec 08
2024
|
Matthew C Kapusta CEO, Managing Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,494
+1.72%
|
-
|
|
Dec 08
2024
|
Christian Klemt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,672
+2.13%
|
-
|
|
Jun 26
2024
|
Walid Abi Saab Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,447
-1.24%
|
$5,788
$4.36 P/Share
|
|
Jun 19
2024
|
Jeremy P. Springhorn Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,080
+20.24%
|
-
|
|
Jun 19
2024
|
Robert Gut Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,080
+13.39%
|
-
|
|
Jun 19
2024
|
David D. Meek Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,080
+22.19%
|
-
|
|
Jun 19
2024
|
Madhavan Balachandran Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,080
+20.24%
|
-
|
|
Jun 19
2024
|
Leonard E Post Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,080
+25.13%
|
-
|
|
Jun 19
2024
|
Jack Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,080
+35.66%
|
-
|
|
Jun 19
2024
|
Rachelle Suzanne Jacques Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,080
+26.43%
|
-
|
|
Jun 17
2024
|
Pierre Caloz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,936
-2.47%
|
$11,744
$4.81 P/Share
|
|
Jun 17
2024
|
Christian Klemt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,611
-0.97%
|
$6,444
$4.8 P/Share
|
|
Jun 13
2024
|
Leonard E Post Director |
SELL
Open market or private sale
|
Direct |
2,222
-12.19%
|
$11,110
$5.14 P/Share
|
|
Jun 13
2024
|
Jeannette Potts Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,781
-4.95%
|
$19,124
$4.98 P/Share
|
|
Jun 13
2024
|
Jeremy P. Springhorn Director |
SELL
Open market or private sale
|
Direct |
2,231
-8.59%
|
$11,155
$5.12 P/Share
|
|
Jun 13
2024
|
David D. Meek Director |
SELL
Open market or private sale
|
Direct |
2,229
-9.92%
|
$11,145
$5.12 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 402K shares |
|---|---|
| Exercise of conversion of derivative security | 100K shares |
| Open market or private sale | 188K shares |
|---|